APEA PMHNP Pre-Predictor Exam
AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines |
APEA PMHNP Pre-Predictor Exam AND ANSWERS ALREADY |
Comprehensive Examination
APEA PMHNP Pre-Predictor Exam AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated
Per Latest Guidelines | Graded A+ actual exam preparation
INTRODUCTION
This document is an important and very helpful preparation
resource for APEA PMHNP Pre-Predictor Exam AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines | Graded A+. Every item uses a
focused exam stem, four response options, a keyed response,
and a clear rationale, making it easier to understand the
subject, spot distractors, and build real exam confidence.
Page 1
, Question 1
A PMHNP is designing a secondary-prevention protocol for a community
mental health center to reduce cardiometabolic mortality among adults
receiving second-generation antipsychotics. Which combination best reflects
current evidence-based standards for structured metabolic monitoring?
A. Baseline BMI, waist circumference, blood pressure, fasting glucose,
and lipids; repeat BMI/BP at each visit and glucose/lipids at 12 weeks
and annually thereafter.
B. Baseline fasting glucose and lipid panel only; repeat annually unless
the patient has a pre-existing diagnosis of diabetes or dyslipidemia.
C. Baseline BMI and blood pressure; obtain HbA1c only if the patient
reports polyuria, polydipsia, or unexplained weight loss.
D. Baseline weight and random glucose; repeat every 6 months with
annual ECG to detect QT prolongation from antipsychotic exposure.
Correct Answer: A - Baseline BMI, waist circumference, blood
pressure, fasting glucose, and lipids; repeat BMI/BP at each visit
and glucose/lipids at 12 weeks and annually thereafter.
RATIONALE
APA/ADA monitoring standards require baseline BMI, waist
circumference, BP, fasting glucose, and lipids with repeat BMI/BP at
each visit and metabolic labs at 12 weeks and annually. Options B-D
omit key parameters (waist circumference, lipids, or early 12-week
follow-up) or substitute non-standard tests (ECG for metabolic risk),
failing to meet guideline-concordant secondary prevention.
Question 2
A patient with schizophrenia has responded only partially to two adequate
trials of different second-generation antipsychotics. Before classifying the
illness as treatment-resistant, which factor most commonly masquerades as
antipsychotic nonresponse and must be excluded?
Page 2
, A. Undetected negative symptom burden
B. Nonadherence to the prescribed antipsychotic
C. Concurrent cannabis use disorder
D. Antipsychotic-induced dysphoria
Correct Answer: B - Nonadherence to the prescribed
antipsychotic
RATIONALE
Nonadherence is the most frequent cause of apparent treatment
resistance and must be objectively excluded (e.g., plasma levels,
long-acting injectable trial) before escalating therapy. Negative
symptoms, cannabis use, and dysphoria can worsen function but do
not by themselves define pharmacologic nonresponse.
Question 3
A patient stabilized on fluoxetine 40 mg daily is prescribed metoprolol for
hypertension. Which pharmacokinetic interaction is most likely to occur?
A. Induction of CYP2D6 leading to reduced metoprolol efficacy
B. Inhibition of CYP2D6 leading to metoprolol toxicity
C. Induction of CYP3A4 leading to reduced fluoxetine levels
D. Inhibition of CYP1A2 leading to increased fluoxetine levels
Correct Answer: B - Inhibition of CYP2D6 leading to metoprolol
toxicity
RATIONALE
Fluoxetine is a potent CYP2D6 inhibitor, and metoprolol is a CYP2D6
substrate; inhibition increases metoprolol levels, risking bradycardia
and hypotension. Fluoxetine does not induce CYP2D6 or CYP3A4,
and metoprolol is not primarily a CYP1A2 substrate.
Page 3
, Question 4
A prepubertal child presents with acute-onset, severe OCD symptoms and
choreiform movements two weeks after group A streptococcal pharyngitis.
Which pathophysiologic mechanism and management step is most consistent
with current evidence?
A. Autoimmune basal ganglia dysfunction; obtain streptococcal titers and
consider immunomodulatory therapy for severe, disabling cases
B. Dopaminergic excess; initiate a high-potency antipsychotic as first-line
C. Serotonergic deficiency; start an SSRI at maximum dose immediately
D. Post-infectious delirium; use benzodiazepines for symptom control
Correct Answer: A - Autoimmune basal ganglia dysfunction;
obtain streptococcal titers and consider immunomodulatory
therapy for severe, disabling cases
RATIONALE
This presentation suggests PANDAS/PANS, an autoimmune basal
ganglia process; obtaining streptococcal titers and considering
immunomodulatory therapy (e.g., IVIG/plasmapheresis) for severe
cases is supported. Antipsychotics and benzodiazepines are not
first-line, and immediate maximum-dose SSRI is not the initial step.
Question 5
Which neurobiological finding most specifically differentiates panic disorder
from generalized anxiety disorder and supports a targeted pharmacologic
rationale?
A. Hyperactive basolateral amygdala with exaggerated fear conditioning
and impaired extinction, responsive to fear-extinction-based exposure
B. Dysregulated noradrenergic locus coeruleus activity with panicogenic
sensitivity to lactate and CO2 challenge, responsive to agents modulating
noradrenergic tone
C. Reduced prefrontal GABA-A receptor density with global cortical
Page 4
AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines |
APEA PMHNP Pre-Predictor Exam AND ANSWERS ALREADY |
Comprehensive Examination
APEA PMHNP Pre-Predictor Exam AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated
Per Latest Guidelines | Graded A+ actual exam preparation
INTRODUCTION
This document is an important and very helpful preparation
resource for APEA PMHNP Pre-Predictor Exam AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines | Graded A+. Every item uses a
focused exam stem, four response options, a keyed response,
and a clear rationale, making it easier to understand the
subject, spot distractors, and build real exam confidence.
Page 1
, Question 1
A PMHNP is designing a secondary-prevention protocol for a community
mental health center to reduce cardiometabolic mortality among adults
receiving second-generation antipsychotics. Which combination best reflects
current evidence-based standards for structured metabolic monitoring?
A. Baseline BMI, waist circumference, blood pressure, fasting glucose,
and lipids; repeat BMI/BP at each visit and glucose/lipids at 12 weeks
and annually thereafter.
B. Baseline fasting glucose and lipid panel only; repeat annually unless
the patient has a pre-existing diagnosis of diabetes or dyslipidemia.
C. Baseline BMI and blood pressure; obtain HbA1c only if the patient
reports polyuria, polydipsia, or unexplained weight loss.
D. Baseline weight and random glucose; repeat every 6 months with
annual ECG to detect QT prolongation from antipsychotic exposure.
Correct Answer: A - Baseline BMI, waist circumference, blood
pressure, fasting glucose, and lipids; repeat BMI/BP at each visit
and glucose/lipids at 12 weeks and annually thereafter.
RATIONALE
APA/ADA monitoring standards require baseline BMI, waist
circumference, BP, fasting glucose, and lipids with repeat BMI/BP at
each visit and metabolic labs at 12 weeks and annually. Options B-D
omit key parameters (waist circumference, lipids, or early 12-week
follow-up) or substitute non-standard tests (ECG for metabolic risk),
failing to meet guideline-concordant secondary prevention.
Question 2
A patient with schizophrenia has responded only partially to two adequate
trials of different second-generation antipsychotics. Before classifying the
illness as treatment-resistant, which factor most commonly masquerades as
antipsychotic nonresponse and must be excluded?
Page 2
, A. Undetected negative symptom burden
B. Nonadherence to the prescribed antipsychotic
C. Concurrent cannabis use disorder
D. Antipsychotic-induced dysphoria
Correct Answer: B - Nonadherence to the prescribed
antipsychotic
RATIONALE
Nonadherence is the most frequent cause of apparent treatment
resistance and must be objectively excluded (e.g., plasma levels,
long-acting injectable trial) before escalating therapy. Negative
symptoms, cannabis use, and dysphoria can worsen function but do
not by themselves define pharmacologic nonresponse.
Question 3
A patient stabilized on fluoxetine 40 mg daily is prescribed metoprolol for
hypertension. Which pharmacokinetic interaction is most likely to occur?
A. Induction of CYP2D6 leading to reduced metoprolol efficacy
B. Inhibition of CYP2D6 leading to metoprolol toxicity
C. Induction of CYP3A4 leading to reduced fluoxetine levels
D. Inhibition of CYP1A2 leading to increased fluoxetine levels
Correct Answer: B - Inhibition of CYP2D6 leading to metoprolol
toxicity
RATIONALE
Fluoxetine is a potent CYP2D6 inhibitor, and metoprolol is a CYP2D6
substrate; inhibition increases metoprolol levels, risking bradycardia
and hypotension. Fluoxetine does not induce CYP2D6 or CYP3A4,
and metoprolol is not primarily a CYP1A2 substrate.
Page 3
, Question 4
A prepubertal child presents with acute-onset, severe OCD symptoms and
choreiform movements two weeks after group A streptococcal pharyngitis.
Which pathophysiologic mechanism and management step is most consistent
with current evidence?
A. Autoimmune basal ganglia dysfunction; obtain streptococcal titers and
consider immunomodulatory therapy for severe, disabling cases
B. Dopaminergic excess; initiate a high-potency antipsychotic as first-line
C. Serotonergic deficiency; start an SSRI at maximum dose immediately
D. Post-infectious delirium; use benzodiazepines for symptom control
Correct Answer: A - Autoimmune basal ganglia dysfunction;
obtain streptococcal titers and consider immunomodulatory
therapy for severe, disabling cases
RATIONALE
This presentation suggests PANDAS/PANS, an autoimmune basal
ganglia process; obtaining streptococcal titers and considering
immunomodulatory therapy (e.g., IVIG/plasmapheresis) for severe
cases is supported. Antipsychotics and benzodiazepines are not
first-line, and immediate maximum-dose SSRI is not the initial step.
Question 5
Which neurobiological finding most specifically differentiates panic disorder
from generalized anxiety disorder and supports a targeted pharmacologic
rationale?
A. Hyperactive basolateral amygdala with exaggerated fear conditioning
and impaired extinction, responsive to fear-extinction-based exposure
B. Dysregulated noradrenergic locus coeruleus activity with panicogenic
sensitivity to lactate and CO2 challenge, responsive to agents modulating
noradrenergic tone
C. Reduced prefrontal GABA-A receptor density with global cortical
Page 4
